Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Glyoxalase system
Biochemistry; detoxification enzyme system

The glyoxalase system is a crucial enzymatic pathway responsible for the detoxification of reactive methylglyoxal and other harmful aldehydes generated during normal metabolism. Found in both bacteria and eukaryotes, this system utilizes two thiol-dependent enzymes: first, glyoxalase I converts the hemithioacetal adduct formed between glutathione and 2-oxoaldehydes into S-2-hydroxyacylglutathione; then, glyoxalase II hydrolyzes these thioesters, producing D-lactate and regenerating glutathione. Unlike enzymes involved in broad-range xenobiotic metabolism, the glyoxalase system exhibits narrow substrate specificity, relying on intracellular thiols to recycle reactive metabolites essential for cellular function.

We don't have any images related to Glyoxalase system yet.
We don't have any YouTube videos related to Glyoxalase system yet.
We don't have any PDF documents related to Glyoxalase system yet.
We don't have any Books related to Glyoxalase system yet.
We don't have any archived web articles related to Glyoxalase system yet.

Overview of Glyoxalase Pathway

The glyoxalase system includes glyoxalase I (GLO1), glyoxalase II (GLO2), and reduced glutathione (GSH). In bacteria, there is an additional enzyme known as glyoxalase III (GLO3), that can function in the absence of GSH. GLO3 has not been found in humans yet.1011 The system pathway begins with methylglyoxal (MG), which is produced from non-enzymatic reactions with DHAP or G3P produced in glycolysis. Methylglyoxal is then converted into S-d-lactoylglutathione by enzyme GLO1 with a catalytic amount of GSH, of which is hydrolyzed into non-toxic D-lactate via GLO2, with liberation of GSH that can be consumed by GLO1 with a new molecule of MG.1213 D-lactate ultimately goes on to be metabolized into pyruvate.14

Regulation

Several small molecule inducers that can activate the glyoxalase pathway by either by promoting GLO1 activity to increase conversion of MG into D-Lactate (GLO1 activators), or by directly reducing MG levels or levels of MG substrate (MG scavengers). GLO1 activators include the synthetic drug candesartan or natural compounds resveratrol, fisetin, the binary combination of trans-resveratrol and hesperetin (tRES-HESP), mangiferin, allyl isothiocyanate, phenethyl isothiocyanate, sulforaphane, and bardoxolone methyl, and MG scavengers including aminoguanidine, alagebrium, and benfotiamine. There is also the small molecule pyridoxamine, which acts as both a GLO1 activator and MG scavenger.15

Many inhibitors of GLO1 have been discovered since GLO1 activity tends to be promoted in cancer cells, thus GLO1 serves as a potential therapeutic target for anti-cancer drug treatment and has been the focus of many research studies regarding its regulation in tumor cells.16

Medical Applications/Pharmacology

Hyperglycemia, a side effect caused by diabetes, combines with oxidative stress to create advanced glycation end-products (AGEs) that can lead to diabetic retinopathy (DR), age related macular degeneration (AMD) and cataracts.1718

Enhancing the glyoxalase system has been shown to delay accumulation of AGEs and associated retinal damage in animals that consume higher glycemic index diets. This was corroborated upon over-expression of GLO1, which in C. elegans reduced basal MG concentration, prevented mitochondrial protein modification and enhanced lifespan. Similarly, in mice, GLO1 over-expression reduced baseline MG concentrations in the brain. In diabetic mice, it prevented diabetes-induced increases in MG modification of glomerular proteins, reduced oxidative stress, and prevented development if diabetic kidney pathology, despite unchanged levels of hyperglycemia.19 Western diets, typically high in glycemic index, exacerbate AGE accumulation and amplify aging-related damage. Enhancing the glyoxalase system may offer a promising therapeutic strategy to prevent the onset and progression of AGEs-related diseases.202122

Oxidative stress can lead to worsening neurological diseases such as Alzheimer's, Parkinson's, and Autism Spectrum Disorder. Flavonoids, a type of antioxidant that combats oxidative stress in the body, has been found to help decrease the production of radical oxygen species (ROS) mostly by preventing the formation of free radicals, additionally they partially enhance the transcription of glyoxalase.23

Retinal pigmented epithelial cells (RPE) and retina have among the highest glyoxalase activities in the body, however, glyoxalase activity is depressed upon aging. This is consistent with observed increases in AGEs associated with aging.2425 Enhancing the glyoxalase system has been shown to delay accumulation of AGEs and associated retinal damage in animals that consume higher glycemic index diets.

Major metabolic pathways converging on the glyoxalase cycle

Although the glyoxalase pathway is the main metabolic system that reduces methylglyoxal levels in the cell, other enzymes have also been found to convert methylglyoxal into non-AGE producing species. Specifically, 99% of MG is processed by glyoxalase metabolism, while less than 1% is metabolized into hydroxyacetone by aldo-keto reductases (AKRs) or into pyruvate by aldehyde dehydrogenases (ALDH).26 Other reactions have been found to produce MG that also feeds into the glyoxalase pathway. These reactions include catabolism of threonine and acetone, peroxidation of lipids, autoxidation of glucose, and degradation of glycated proteins.27

See also

  • Antioxidant – Compound that inhibits the oxidation of other molecules
  • Advanced glycation endproduct – Proteins or lipids chemically altered by sugar exposurePages displaying short descriptions of redirect targets

References

  1. Vander Jagt DL (1989). "15. The glyoxalase system". In Dolphin D, Poulson R, Avramovic O (eds.). Glutathione: Chemical, Biochemical and Medical Aspects. Part A. Coenzymes and cofactors. Wiley. pp. 597–641. ISBN 9780471097846. OCLC 18222786. 9780471097846 ↩

  2. Farrera, Dominique; Galligan, James (September 2022). "The Human Glyoxalase Gene Family in Health and Disease". Chemical Research in Toxicology. 35 (10): 1766–1776. doi:10.1021/acs.chemrestox.2c00182. PMC 10013676. PMID 36048613. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013676 ↩

  3. Farrera, Dominique; Galligan, James (September 2022). "The Human Glyoxalase Gene Family in Health and Disease". Chemical Research in Toxicology. 35 (10): 1766–1776. doi:10.1021/acs.chemrestox.2c00182. PMC 10013676. PMID 36048613. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013676 ↩

  4. Dixon DP, Cummins L, Cole DJ, Edwards R (June 1998). "Glutathione-mediated detoxification systems in plants". Current Opinion in Plant Biology. 1 (3): 258–66. Bibcode:1998COPB....1..258D. doi:10.1016/S1369-5266(98)80114-3. PMID 10066594. /wiki/Bibcode_(identifier) ↩

  5. Inoue Y, Kimura A (1995). "Methylglyoxal and regulation of its metabolism in microorganisms". Advances in Microbial Physiology. 37: 177–227. doi:10.1016/S0065-2911(08)60146-0. ISBN 9780120277377. PMID 8540421. 9780120277377 ↩

  6. Thornalley PJ (December 2003). "Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation". Biochemical Society Transactions. 31 (Pt 6): 1343–8. doi:10.1042/BST0311343. PMID 14641060. /wiki/Doi_(identifier) ↩

  7. Creighton DJ, Hamilton DS (March 2001). "Brief history of glyoxalase I and what we have learned about metal ion-dependent, enzyme-catalyzed isomerizations". Archives of Biochemistry and Biophysics. 387 (1): 1–10. doi:10.1006/abbi.2000.2253. PMID 11368170. /wiki/Doi_(identifier) ↩

  8. Vander Jagt DL (May 1993). "Glyoxalase II: molecular characteristics, kinetics and mechanism". Biochemical Society Transactions. 21 (2): 522–7. doi:10.1042/bst0210522. PMID 8359524. /wiki/Doi_(identifier) ↩

  9. Dixon DP, Cummins L, Cole DJ, Edwards R (June 1998). "Glutathione-mediated detoxification systems in plants". Current Opinion in Plant Biology. 1 (3): 258–66. Bibcode:1998COPB....1..258D. doi:10.1016/S1369-5266(98)80114-3. PMID 10066594. /wiki/Bibcode_(identifier) ↩

  10. Farrera, Dominique; Galligan, James (September 2022). "The Human Glyoxalase Gene Family in Health and Disease". Chemical Research in Toxicology. 35 (10): 1766–1776. doi:10.1021/acs.chemrestox.2c00182. PMC 10013676. PMID 36048613. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013676 ↩

  11. He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. (November 2020). "Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators". Biomedicine & Pharmacotherapy. 131: 110663. doi:10.1016/j.biopha.2020.110663. PMID 32858501. https://doi.org/10.1016%2Fj.biopha.2020.110663 ↩

  12. Farrera, Dominique; Galligan, James (September 2022). "The Human Glyoxalase Gene Family in Health and Disease". Chemical Research in Toxicology. 35 (10): 1766–1776. doi:10.1021/acs.chemrestox.2c00182. PMC 10013676. PMID 36048613. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013676 ↩

  13. Aragonès, Gemma; Rowan, Sheldon; Francisco, Sarah G.; Whitcomb, Elizabeth A.; Yang, Wenxin; Perini-Villanueva, Giuliana; Schalkwijk, Casper G.; Taylor, Allen; Bejarano, Eloy (2021-07-22). "The Glyoxalase System in Age-Related Diseases: Nutritional Intervention as Anti-Ageing Strategy". Cells. 10 (8): 1852. doi:10.3390/cells10081852. ISSN 2073-4409. PMC 8393707. PMID 34440621. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393707 ↩

  14. He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. (November 2020). "Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators". Biomedicine & Pharmacotherapy. 131: 110663. doi:10.1016/j.biopha.2020.110663. PMID 32858501. https://doi.org/10.1016%2Fj.biopha.2020.110663 ↩

  15. He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. (November 2020). "Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators". Biomedicine & Pharmacotherapy. 131: 110663. doi:10.1016/j.biopha.2020.110663. PMID 32858501. https://doi.org/10.1016%2Fj.biopha.2020.110663 ↩

  16. He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. (November 2020). "Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators". Biomedicine & Pharmacotherapy. 131: 110663. doi:10.1016/j.biopha.2020.110663. PMID 32858501. https://doi.org/10.1016%2Fj.biopha.2020.110663 ↩

  17. Bejarano, Eloy; Domenech-Bendaña, Alicia; Avila-Portillo, Norma; Rowan, Sheldon; Edirisinghe, Sachini; Taylor, Allen (July 2024). "Glycative stress as a cause of macular degeneration". Progress in Retinal and Eye Research. 101: 101260. doi:10.1016/j.preteyeres.2024.101260. ISSN 1873-1635. PMC 11699537. PMID 38521386. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699537 ↩

  18. Aragonès G, Rowan S, G Francisco S, Yang W, Weinberg J, Taylor A, Bejarano E (October 2020). "Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy". Antioxidants. 9 (11): 1062. doi:10.3390/antiox9111062. PMC 7692619. PMID 33143048. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692619 ↩

  19. Aragonès G, Rowan S, G Francisco S, Yang W, Weinberg J, Taylor A, Bejarano E (October 2020). "Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy". Antioxidants. 9 (11): 1062. doi:10.3390/antiox9111062. PMC 7692619. PMID 33143048. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692619 ↩

  20. Aragonès G, Rowan S, G Francisco S, Yang W, Weinberg J, Taylor A, Bejarano E (October 2020). "Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy". Antioxidants. 9 (11): 1062. doi:10.3390/antiox9111062. PMC 7692619. PMID 33143048. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692619 ↩

  21. Bejarano, Eloy; Domenech-Bendaña, Alicia; Avila-Portillo, Norma; Rowan, Sheldon; Edirisinghe, Sachini; Taylor, Allen (July 2024). "Glycative stress as a cause of macular degeneration". Progress in Retinal and Eye Research. 101: 101260. doi:10.1016/j.preteyeres.2024.101260. ISSN 1873-1635. PMC 11699537. PMID 38521386. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699537 ↩

  22. Francisco, Sarah G.; Smith, Kelsey M.; Aragonès, Gemma; Whitcomb, Elizabeth A.; Weinberg, Jasper; Wang, Xuedi; Bejarano, Eloy; Taylor, Allen; Rowan, Sheldon (2020-09-18). "Dietary Patterns, Carbohydrates, and Age-Related Eye Diseases". Nutrients. 12 (9): 2862. doi:10.3390/nu12092862. ISSN 2072-6643. PMC 7551870. PMID 32962100.{{cite journal}}: CS1 maint: unflagged free DOI (link) https://pubmed.ncbi.nlm.nih.gov/32962100 ↩

  23. Frandsen JR, Narayanasamy P (April 2018). "Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway". Redox Biology. 14: 465–473. doi:10.1016/j.redox.2017.10.015. PMC 5680520. PMID 29080525. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680520 ↩

  24. Aragonès G, Rowan S, G Francisco S, Yang W, Weinberg J, Taylor A, Bejarano E (October 2020). "Glyoxalase System as a Therapeutic Target against Diabetic Retinopathy". Antioxidants. 9 (11): 1062. doi:10.3390/antiox9111062. PMC 7692619. PMID 33143048. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692619 ↩

  25. Bejarano, Eloy; Domenech-Bendaña, Alicia; Avila-Portillo, Norma; Rowan, Sheldon; Edirisinghe, Sachini; Taylor, Allen (July 2024). "Glycative stress as a cause of macular degeneration". Progress in Retinal and Eye Research. 101: 101260. doi:10.1016/j.preteyeres.2024.101260. ISSN 1873-1635. PMC 11699537. PMID 38521386. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11699537 ↩

  26. He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. (November 2020). "Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators". Biomedicine & Pharmacotherapy. 131: 110663. doi:10.1016/j.biopha.2020.110663. PMID 32858501. https://doi.org/10.1016%2Fj.biopha.2020.110663 ↩

  27. He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. (November 2020). "Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators". Biomedicine & Pharmacotherapy. 131: 110663. doi:10.1016/j.biopha.2020.110663. PMID 32858501. https://doi.org/10.1016%2Fj.biopha.2020.110663 ↩